1 / 12

Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis

Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis. Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8. Objectives of Meta-Analysis. 1. Provide a more precise estimate of enoxaparin’s effects on: - death + cardiac ischemic events - major hemorrhage

chana
Télécharger la présentation

Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  2. Objectives of Meta-Analysis 1. Provide a more precise estimate of enoxaparin’s effects on: - death + cardiac ischemic events - major hemorrhage 2. Determine onset and duration of treatment effect with enoxaparin Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  3. TIMI 11 B ESSENCE IV UFH Bolus 70 U/kg 5000 U Infusion 15 U/kg/h 1000 U/h aPTT (x control) 1.5-2.5 1.5-2.5 Med Dur. Rx (d) 3.0 2.6 Enoxaparin (Acute) Bolus30 mg None S.C. Q 12 h (mg/kg) 1.0 1.0 Med Dur. Rx (d)4.6 2.6 Enoxaparin (Chronic-43 d) 40 mg (<65 kg) None 60 mg (>65 kg) Comparison of Trials: Dose of Study Rx Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  4. TIMI 11 B ESSENCE (%) (%) Age (y) 66 64 Diabetes Mellitus 20% 22% Current Smoker 27% 24% HTN 50% 54% Prior MI 32% 46% ECG: ST dev 37% 29% Normal 36% 44% Presenting Ilness: Uns Ang 59% 69% NQMI 34% 21% Comparison of Trials: Patient Characteristics Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  5. Methods • Prespecified EndpointsDeath Death/MI/Urg Revasc Death/MI Major hemorrhage • Pooling Procedures : Odds Ratio (95%CI)Peto Method Mantel-Haenszel Method DerSimonian + Laird Method • Heterogeneity Testing Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  6. N UFH(%) Enox(%) OR % p 3910 TIMI 11B B 3171 8 ESSENCE B 0.79(0.69-0.91) 7081 0.001 21 13.5 11.0 OVERALL 3910 TIMI 11B B 3171 43 ESSENCE B 0.80(0.71-0.91) 0.0005 20 7081 18.8 15.6 OVERALL 0.5 0.6 0.7 0.8 0.9 1 2 Enox Better Odds Ratio UFH Better Enoxaparin for UA/NQMI:TIMI 11B-ESSENCE Meta-AnalysisDeath/MI/Urgent Revasc Day Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  7. TIMI 11B-ESSENCE Meta-AnalysisDeath/MI/Urgent Revasc Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  8. N Enox(%) Day UFH(%) OR p % TIMI 11B 3910 B ESSENCE 8 3171 OVERALL 7081 5.3 4.1 0.77(0.62-0.95) 0.02 23 B 3910 TIMI 11B B 3171 ESSENCE 43 B 0.82(0.69-0.97) 18 0.02 OVERALL 7081 8.6 7.1 B 0.5 0.6 0.7 0.8 0.9 1 2 Enox Better Odds Ratio UFH Better Enoxaparin for UA/NQMI:TIMI 11B-ESSENCE Meta-AnalysisDeath/MI Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  9. TIMI 11B-ESSENCE Meta-AnalysisDeath/MI Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  10. Early Rx Phase : TIMI 11 B vs ESSENCE Death/MI /Urgent Revasc. 9 8 7.3 % TIMI 11 B RRR 24% P=0.03 UFH 7 ENOX 6 ESSENCE 5.5 % 5 5.2 % % Pts 4 RRR 18% P=0.21 4.2 % 3 2 1 0 0 8 16 24 32 40 48 56 64 72 Hours from Randomization Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  11. Major Hemorrhage (Wgt Adj Rx) OR(95 CI) Enox (%) UFH(%) P TIMI 11B 1.5 1.0 1.52(0.86-2.69) NS 0.91(0.47-1.78) NS 1.1 1.2 ESSENCE OVERALL 1.23(0.80-1.89) 1.3 1.1 NS Favors ENOX Favors UFH 0.5 1 2 Heterogeneity: All P=NS O.R. Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

  12. Conclusions Efficacy 20% in death and cardiac ischemic events Early onset of benefit (48 hours) Durable treatment effect (43 days) Safety No significant in major hemorrhage (wgt adj Rx) Clinical Implications--New Therapeutic StandardEnoxaparin is antithrombin for acute management of UA/NQMI Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8

More Related